TrialResults - center   -  Clinical trials results database in cardiology

GAMMA

You are here:  Home > New trials (ongoing)

Ongoing or excluded trials recently added

03/03/2010 - (TRA 2 degrees P)-TIMI 50  -  SCH 530348 2.5 mg daily versus placebo

  cardiovascular prevention - antiplatelets drug - all type of patients

  cardiovascular prevention - antiplatelets drug - secondary prevention in patients with intermittent claudication

  cardiovascular prevention - antiplatelets drug - secondary prevention in patients with CAD

29/01/2010 - CABANA  -  left atrial catheter ablation versus current state-of-the-art therapy with either rate control or rhythm control drugs

  atrial fibrillation - catheter ablation - all type of patients

16/01/2010 - B0661004  -  Apixaban 2.5 or 5 mg twice daily versus placebo

  acute coronary syndrome - antithrombotics - all type of patient

  acute coronary syndrome - anticoagulant - All ACS (including AMI)

  acute coronary syndrome - direct factor Xa inhibitors - all type of patients

  acute coronary syndrome - antithrombotics - patients with a recent ACS

16/01/2010 - APPRAISE 2 (CV185-068)  -  apixaban 5mg twice daily versus placebo

  acute coronary syndrome - antithrombotics - all type of patient

  acute coronary syndrome - anticoagulant - All ACS (including AMI)

  acute coronary syndrome - direct factor Xa inhibitors - all type of patients

  acute coronary syndrome - antithrombotics - patients with a recent ACS

16/01/2010 - ARISTOTLE (CV185-030)  -  apixaban 5mg twice daily versus warfarin adjusted for an INR between 2 and 3

  atrial fibrillation - antithrombotics - primary prevention of thromboembolic events

  atrial fibrillation - direct factor Xa inhibitors - all type of patients

  atrial fibrillation - new oral anticoagulant - all type of patients

16/01/2010 - AVERROES (CV185-048)  -  apixaban 5 mg (or 2.5 mg) twice daily versus aspirin 81-324 md daily

  atrial fibrillation - antithrombotics - primary prevention of thromboembolic events

  atrial fibrillation - direct factor Xa inhibitors - all type of patients

  atrial fibrillation - new oral anticoagulant - all type of patients

16/01/2010 - B0661003  -  apixaban 5 or 2.5 mg twice daily versus warfarin

  atrial fibrillation - antithrombotics - primary prevention of thromboembolic events

  atrial fibrillation - direct factor Xa inhibitors - all type of patients

  atrial fibrillation - new oral anticoagulant - all type of patients

14/01/2010 - CV185-036  -  apixaban 2.5mg twice daily, 30 days versus enoxaparin 40mg once daily 6-14 days

  DVT prophylaxis - anticoagulant - orthopedic surgery

  DVT prophylaxis - direct factor Xa inhibitors - all type of patients

  DVT prophylaxis - new oral anticoagulant - all type of patients

18/12/2009 - INNOVATE  -  versus

  acute myocardial infarction - antiplatelets drug - all type of patients

23/10/2009 - NCT00494871  -  rivaroxaban 10mg daily versus warfarin adjusted dose

  atrial fibrillation - antithrombotics - primary prevention of thromboembolic events

  atrial fibrillation - direct factor Xa inhibitors - all type of patients

  atrial fibrillation - new oral anticoagulant - all type of patients

23/10/2009 - Einstein-DVT Evaluation  -  Rivaroxaban versus Enoxaparin followed by VKA

  venous thrombosis - antithrombotics - all type of patients

  venous thrombosis - direct factor Xa inhibitors - all type of patients

23/10/2009 - Einstein-PE Evaluation  -  versus

  venous thrombosis - antithrombotics - all type of patients

  venous thrombosis - direct factor Xa inhibitors - all type of patients

23/09/2009 - MARVEL  -  autologous myoblasts by intramyocardial injection at doses containing 400 or 800 million cells versus sham procedure

  acute myocardial infarction - cell-based therapies - PCI

21/09/2009 - ESTATE  -  atorvastatin given immediately before PCI versus

  percutaneous coronary intervention - statin - all type of patients

18/09/2009 - DAPT  -  additional 18 months of thienopyridine treatment versus placebo

  stent - antithrombotics - all type of patients

  percutaneous coronary intervention - antithrombotics - PCI with stent placement

18/09/2009 - BRAVE-4  -  Prasugrel + Bivalirudin versus Clopidogrel + Heparin

  percutaneous coronary intervention - antithrombotics - all type of patients

13/09/2009 - NCT00975234  -  Intra-lesion injection of autologous skeletal myoblasts versus placebo

  acute myocardial infarction - cell-based therapies - PCI

26/08/2009 - CURRENT OASIS 7 (clopidogrel)  -  versus

  acute coronary syndrome - antithrombotics - all type of patient

  acute coronary syndrome - antiplatelets drug - ACS (excluding AMI)

  acute coronary syndrome - antiplatelets drug - all type of patients

26/08/2009 - CURRENT - OASIS 7 (ASA)  -  versus

  acute coronary syndrome - antithrombotics - all type of patient

  acute coronary syndrome - antiplatelets drug - ACS (excluding AMI)

  acute coronary syndrome - antiplatelets drug - all type of patients

21/07/2009 - PLAATO  -  versus

  atrial fibrillation - embolic protection - all type of patients

20/07/2009 - ENGAGE-AF TIMI 48  -  edoxaban 30 or 60mg once daily versus warfarin (INR 2-3)

  atrial fibrillation - antithrombotics - primary prevention of thromboembolic events

  atrial fibrillation - direct factor Xa inhibitors - all type of patients

  atrial fibrillation - new oral anticoagulant - all type of patients

20/07/2009 - EmbraceAC  -  tecarfarin versus warfarin

  atrial fibrillation - antithrombotics - primary prevention of thromboembolic events

14/07/2009 - TRANSFER-AMI  -  pharmacoinvasive strategy (transfer for PCI within six hours of fibrinolysis) versus standard treatment after fibrinolysis (rescue PCI for failed reperfusion, with elective PCI encouraged for successfully reperfused patients after 24 hours)

  acute myocardial infarction - myocardial revascularization - all type of patients

This site complies to the HONcode standard for trustworthy health information: verify here.

Last uptaded on 2010/3 51 user(s) connected

TrialResults-center database by TrialResults-center is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France License .

OpenSearch feed - Add TrialResults-center.org to your browser's search bar